Clinical Trial

BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

Withdrawn Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Due to corporate strategic adjustment.
Summary
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-19.
Status change: Not Yet Recruiting → Withdrawn 2026-05-26
Trial Details
NCT Number NCT07196124
Lead Sponsor Guangzhou Bio-gene Technology Co., Ltd
Conditions Multiple Myeloma Refractory
Start Date 2025-10-10
Primary Completion 2028-10-09 (estimated)
Study Completion 2028-12-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-28